Dietary cyclic dipeptides, apoptosis and psychiatric disorders: A hypothesis

Medical Hypotheses

Volumn 82, Issue 6, 2014, Pages 740-743

  Semon, Bruce A ^a  

^a Wisconsin Institute of Nutrition   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; DIPEPTIDE; DOPAMINE RECEPTOR; ERGOT ALKALOID; GLUTAMATE TRANSPORTER; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; PHENYLALANINE; PROLINE;

ALZHEIMER DISEASE; AMINO ACID METABOLISM; APOPTOSIS; ARTICLE; AUTISM; BRAIN DEVELOPMENT; BRAIN ISCHEMIA; CANDIDA ALBICANS; CARBON METABOLISM; CHILDHOOD; CONFUSION; DEPRESSION; FETUS DEVELOPMENT; HUMAN; MALT; MENTAL DISEASE; NEUROPATHOLOGY; NEUROPHYSIOLOGY; NEUROTRANSMISSION; NONHUMAN; PARKINSON DISEASE; PROTEIN INTAKE; SCHIZOPHRENIA; BIOLOGICAL MODEL; BIOSYNTHESIS; CHEMICALLY INDUCED; DRUG EFFECTS; INTESTINE; METABOLISM; MICROBIOLOGY; PHYSIOLOGY;

APOPTOSIS; CANDIDA ALBICANS; DIPEPTIDES; HUMANS; INTESTINES; MENTAL DISORDERS; MODELS, BIOLOGICAL;

EID: 84899650841     PISSN: 03069877     EISSN: 15322777     Source Type: Journal    
DOI: 10.1016/j.mehy.2014.03.016     Document Type: Article

References (55)

1. Sakamura S., Katsuhisa F., Kasai T. Bitter diketopiperazines in roasted malts for beer brewing. Agric Biol Chem 1978, 3:607-612.
2. Theobald D.S., Peters F.T., Beyer J., Ewald A.H., Maurer H.H. GC-MS detection of dihydroergotamine artifact-proof of ingestion of dihydroergotamine?. Toxichem + Krimtech. Mitteilungsblatt der Gesellschaft fur Toxikologische and "Forensische Chemie" 2005, 72(2):81-84.
3. Brauns S.C., Milne P., Naude R., Van De Venter M. Selected cyclic dipeptides inhibit cancer cell growth and induce apoptosis in HT-29 colon cancer cells. Anticancer Res 2004, 24:1713-1720.
4. Brauns S.C., Dealtry G., Milne P., Naude R., Van De Venter M Caspase-3 activation and induction of parp cleavage by cyclic dipeptide cyclo(phe-pro) in HT-29 cells. Anticancer Res 2005, 25:4197-4202.
5. Lingappa B.T., Prasad M., Lingappa Y., Hunt D.F., Biemann K. Phenethyl alcohol and tryptophol: autoantibiotics produced by fungus Candida albicans. Science 1969, 163:192-193.
6. Revett T.J., Baker G.B., Jhamandas J., Kar S. Glutamate system, amyloid ß peptides and tau protein: functional interrelationships and relevance to Alzheimer disease pathology. J Psychiatry Neurosci 2013, 38(1):6-23.
7. Egerton A., Stone J.M. The glutamate hypothesis of schizophrenia: neuroimaging and drug development. Curr Pharm Biotechnol 2012, 13(8):1500-1512.
8. Javitt D.C. Glycine transport inhibitors in the treatment of schizophrenia. Handb Exp Pharmacol 2012, 213:367-399.
9. Nunes E.A., MacKenzie E.M., Rossolatos D., Perez-Parada J., Baker G.B., Dursun S.M. d-Serine and schizophrenia: an update. Expert Rev Neurother 2012, 12(7):801-812.
10. Fuso A., Scarpa S. One-carbon metabolism and Alzheimer's disease: is it all a methylation matter?. Neurobiol Aging 2011, 32(7):1192-1195.
11. Krebs M.O., Bellon A., Mainguy G., Jay T.M., Frieling H. One-carbon metabolism and schizophrenia: current challenges and future directions. Trends Mol Med 2009, 15(12):562-570.
12. Misiak B., Frydecka D., Piotrowski P., Kiejna A. The multidimensional nature of metabolic syndrome in schizophrenia: lessons from studies of one-carbon metabolism and DNA methylation. Epigenomics 2013, 3:317-329.
13. Prasad C. Bioactive cyclic dipeptides. Peptides 1995, 16(1):151-164.
14. Walter R., Ritzmann F.F., Bhargava H.N., Flexner L.B. Prolyl leucyl-glycinamide, cyclo (Leu-Gly) and derivatives block development of physical dependence on morphine in mice. Proc. Natl. Acad. Sci. USA 1979, 76:518-520.
15. Bhargava H.N. Cyclo (leucylglycin) inhibits the development of morphine induced analgesic tolerance and dopamin receptor supersensitivity in rats. Life Sci. 1980, 27(2):17-23.
16. Bhargava H.N., Ritzmann R.F. Inhibition of neuroleptic-induced dopamine receptor supersensitivity by cyclo (Leu-Gly). Pharmacol Biochem Behav 1980, 13(5):633-636.
17. Furukawa T., Akutagawa T., Funatani H., Uchida T., Hotta Y., Niwa M., et al. Cyclic dipeptides exhibit potency for scavenging radicals. Bioorg Med Chem 2012, 20(6):2002-2009.
18. Ben-Shachar D., Laifenfeld D. Mitochondria, synaptic plasticity, and schizophrenia. Int Rev Neurobiol 2004, 59:273-296.
19. Tyagi N., Moshal K.S., Ovechkin A.V., Rodriguez W., Steed M., Henderson B., et al. Mitochondrial mechanism of oxidative stress and systemic hypertension in hyperhomocysteinemia. J Cell Biochem 2005, 96(4):665-671.
20. Margolis R.L., Chuang D.M., Post R.M. Programmed cell death: implications for neuropsychiatric disorders. Biol Psychiatry 1994, 35:946-956.
21. Oppenheim R.W. Cell death during development of the nervous system. Ann Rev Neurosci 1991, 14:453-501.
22. Benes F.M., Davidson J., Bird E.D. Quantitative cytoarchitectural studies of the cerebral cortex of schizophrenics. Arch Gen Psychiatry 1986, 43:31-35.
23. Benes F.M., McSparren J., Bird E.D., et al. Deficits in small interneurons in prefrontal and cingulate cortices of schizophrenic and schizoaffective patients. Arch Gen Psychiatry 1991, 48:996-1001.
24. Falkai P., Bogerts B., Rozumek M. Limbic pathology in schizophrenia: the entorhinal region-a morphometric study. Biol Psychiatry 1988, 24:515-521.
25. Akbarian S., Bunney W.E., Potkin S.G., et al. Altered distribution of nicotinamide-adenine dinucleotide phosphate-diaphorase cells in frontal lobe of schizophrenics implies disturbances of cortical development. Arch Gen Psychiatry 1993, 50:169-177.
26. Rajkowska G., Selemon L.D., Goldman-Rakic P.S. Neural and glial somal size in the prefrontal cortex: a postmortem morphometric study of schizophrenia and Huntington disease. Arch Gen Psychiatry 1998, 55:215-224.
27. Pierri J.N., Vok C.L., Auh S., Sampson A., Lewis D.A. Decreased somal size of deep layer 3 pyramidal neurons in the prefrontal cortex of subjects with schizophrenia. Arch Gen Psychiatry 2001, 2001(58):466-473.
28. Akbarian S., Kim J.J., Potkin S.G., Hetrick W.P., Bunney W.E., Jones E.G. Maldistribution of interstitial neurons in prefrontal white matter of the brains of schizophrenic patients. Arch Gen Psychiatry 1996, 53:425-436.
29. Shenton M.E., Dickey C.C., Frumin M., McCarley R.W. A review of MRI findings in schizophrenia. Schizophr Res 2001, 2001(49):1-52.
30. Zipursky R.B., Lim K.O., Sullivan E.V., Brown B.W., Pfeffer-baum A. Widespread cerebral gray matter volume deficits in schizophrenia. Arch Gen Psychiatry 1992, 1992(49):195-205.
31. Schlaepfer T.E., Harris G.J., Tien A.Y., Peng L.W., Lee S., Federman E.B., et al. Decreased regional cortical gray matter volume in schizophrenia. Am J Psychiatry 1994, 151:842-848.
32. Weinberg D.R., Berman K.F., Zee R.F. Physiologic dysfunction of dorsolateral prefrontal cortex in schizophrenia. I. Regional cerebral blood flow evidence. Arch Gen Psychiatry 1986, 43:114-124.
33. Wible C.G., Kubicki M., Yoo S.S., Kacher D.F., Salisbury D.F., Anderson M.C., et al. A functional magnetic resonance imaging study of auditory mismatch in schizophrenia. Am J Psychiatry 2001, 158:938-943.
34. Garey L.J., Ong W.Y., Patel T.S., Kanani M., Davis A., Mortimer A.M., et al. Reduced dendritic spine density on cerebral cortical pyramidal neurons in schizophrenia. J Neurol Neurosurg Psychiatry 1998, 65:446-453.
35. Glantz L.A., Lewis D.A. Decreased dendritic spine density on prefrontal cortical pyramidal neurons in schizophrenia. Arch Gen Psychiatry 2000, 57:65-73.
36. Glantz L.A., Gilmore J.H., Lieberman J.A., Jarskog L.F. Apoptotic mechanisms and the synaptic pathology of schizophrenia. Schizophr Res 2006, 81(1):47-63.
37. Bauman M.L. Microscopic neuroanatomic abnormalities in autism. Pediatrics 1991, 87(suppl):791-796.
38. Carper R.A., Moses P., Tigue Z.D., Courchesne E. Cerebral lobes in autism: early hyperplasia and abnormal age effect. Neuroimage 2002, 16:1038-1051.
39. Carper R., Courchesne E. Localized enlargement of the frontal lobe in autism. Biol Psychiatry 2005, 57:26-133.
40. Courchesne E., Pierce K. Why the frontal cortex in autism might be talking only to itself: local over-connectivity but long-distance disconnection. Curr Opin Neurobiol 2005, 15:225-230.
41. Mattson M.P., Duan W., Pedersen W.A., Culmsee C. Neurodegenerative disorders and ischemic brain disease. Apoptosis 2001, 6:69-81.
42. Mattson M.P., Pedersen W.A., Duan W., Culmsee C., Camandola S. Cellular and molecular mechanisms underlying perturbed energy metabolism and neuronal degeneration in Alzheimer's and Parkinson's diseases. Ann N Y Acad Sci 1999, 893:154-175.
43. Jenner P., Olanow C.W. Understanding cell death in Parkinson's disease. Ann Neurol 1998, 44:S72-S84.
44. Dirnagl U., Ladecola C., Moskowitz M.A. Pathobiology of ischaemic stroke: an integrated view. Trends Neurosci 1999, 22:391-397.
45. Ginz M., Engelhardt U.H. Identification of proline-based diketopiperazines in roasted coffee. J Agric Food Chem 2000, 48. 3528-3252.
46. Gautschi M., Schmid J.P. Chemical characterization of diketopiperazines in beer. J Agric Food Chem 1997, 45:3183-3189.
47. Takahashi K., Tadenuma M., Katamoto K., Sato S. Agric Biol Chem 1974, 38:926-932.
48. Samonis G., Anaissie E.J., Bodey G.P. Effects of broad spectrum antimicrobial agents on yeast colonization of the gastrointestinal tracts of mice. Antimicrob Agents Chemother 1990, 34:2420-2422.
49. Gamet-Payrastre L., Lumeau S., Gase N., Cassar G., Rollin P., Tulliez J. Selective cytostatic and cytotoxic effect of glucosinolate hydrolysis products on human colon cancer cells in vitro. Anticancer Drugs 1998, 9:141-148.
50. Richardson M.D., Smith H. Resistance of virulent and attenuated strains of Candida albicans to intracellular killing by human and mouse phagocytes. J Infect Dis 1981, 144(6):557-564.
51. Lehner T., Wilton J.M.A., Ivanyi L. Immunodeficiencies in Chronic muco-cutaneous candidiases. Immunology 1972, 22:775-787.
52. McDowell R.S., Gadek T.R. Structural studies of potent constrained RGD peptides. J Am Chem Soc 1992, 114:9245-9253.
53. Masliah E., Mallory M., Alford M., Hansen L.A. Caspase dependent DNA fragmentation might be associated with excitotoxicity in Alzheimer disease. J Neuropathol Exp Neurol 1998, 57(11):1041-1052.
54. Semon B, Kornblum L. An Extraordinary Power to Heal. Wisconsin Institute of, Nutrition. 2003. pp. 92-118, 129-134.
55. Gilman A.G., Goodman L.S., Gilman A. Goodman and Gilman's The Pharmacological Basis of Therapeutics 1980, 6th ed., Macmillan Publishing Co., New York, p. 945.